Sökning: WFRF:(Lindén Thomas 1962 ) >
A systematic review...
A systematic review and meta-analysis of erythropoietin in experimental stroke.
-
- Jerndal, Mikael (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
- Forsberg, Kalle (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
Sena, Emily S (författare)
-
visa fler...
-
Macleod, Malcolm R (författare)
-
O'Collins, Victoria E (författare)
-
- Lindén, Thomas, 1962 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
- Nilsson, Michael, 1962 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering,Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
-
Howells, David W (författare)
-
visa färre...
-
(creator_code:org_t)
- 2009-12-30
- 2010
- Engelska.
-
Ingår i: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. - : SAGE Publications. - 1559-7016. ; 30:5, s. 961-8
- Relaterad länk:
-
https://journals.sag...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Erythropoietin (EPO) has shown promise as a neuroprotectant in animal models of ischemic stroke. EPO is thought not only to protect neurons from cell death, but also to promote regeneration after stroke. Here, we report a systematic review and meta-analysis of the efficacy of EPO in animal models of focal cerebral ischemia. Primary outcomes were infarct size and neurobehavioral outcome. Nineteen studies involving 346 animals for infarct size and 425 animals for neurobehavioral outcome met our inclusion criteria. Erythropoietin improved infarct size by 30.0% (95% CI: 21.3 to 38.8) and neurobehavioral outcome by 39.8% (33.7 to 45.9). Studies that randomized to treatment group or that blinded assessment of outcome showed lower efficacy. Erythropoietin was tested in animals with hypertension in no studies reporting infarct size and in 7.5% of the animals reporting neurobehavioral outcome. These findings show efficacy for EPO in experimental stroke, but when the impact of common sources of bias are considered, this efficacy falls, suggesting we may be overestimating its potential benefit. As common human co-morbidities may reduce therapeutic efficacy, broader testing to delineate the range of circumstances in which EPO works best would be beneficial.
Nyckelord
- Animals
- Behavior
- Animal
- drug effects
- Brain Ischemia
- drug therapy
- pathology
- Databases
- Factual
- Disease Models
- Animal
- Erythropoietin
- pharmacology
- therapeutic use
- Humans
- Hypertension
- drug therapy
- pathology
- Neuroprotective Agents
- pharmacology
- therapeutic use
- Stroke
- drug therapy
- pathology
Publikations- och innehållstyp
- ref (ämneskategori)
- for (ämneskategori)
Hitta via bibliotek
Till lärosätets databas